MedTrace Logo

Biological Changes Associated With High Risk of Preeclampsia in Nulliparous Women

NCT06200571 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-12-12

No results posted yet for this study

Summary

Primary outcome

1. to identify biological changes in nulliparous women at high risk for preeclampsia defined by combined screening by Fetal Medicine Foundation (FMF)
2. to identify biological effects of aspirin in nulliparous women with high risk for preeclampsia

Secondary outcomes include findings of longitudinal development and predictive potential of biological markers associated with high-risk for preeclampsia and aspirin treatment.

The main questions it aims to answer are:

* Is high risk for preeclampsia associated with biological changes during pregnancy?
* How does aspirin modulate the biological changes associated with high risk for preeclampsia?

Nulliparous women will undergo routine clinical care at two regional hospitals with different treatment strategies, and selected to the study in three groups: low risk of preeclampsia, high risk of preeclampsia without aspirin, and high-risk of preeclampsia with aspirin treatment.

Conditions

Sponsors & Collaborators

  • Alesund Hospital

    collaborator OTHER

  • St. Olavs Hospital

    collaborator OTHER

  • Norwegian University of Science and Technology

    lead OTHER

Principal Investigators

  • Ann-Charlotte Iversen, Professor · Norwegian University of Science and Technology

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-22
Primary Completion
2026-12-31
Completion
2032-12-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06200571 on ClinicalTrials.gov